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Background. Pediatric diarrheal disease presents a major public health burden in low- to middle-income countries. The clinical 
benefits of empirical antimicrobial treatment for diarrhea are unclear in settings that lack reliable diagnostics and have high anti-
microbial resistance (AMR).
Methods. We conducted a prospective multicenter cross-sectional study of pediatric patients hospitalized with diarrhea con-
taining blood and/or mucus in Ho Chi Minh City, Vietnam. Clinical parameters, including disease outcome and treatment, were 
measured. Shigella, nontyphoidal Salmonella (NTS), and Campylobacter were isolated from fecal samples, and their antimicrobial 
susceptibility profiles were determined. Statistical analyses, comprising log-rank tests and accelerated failure time models, were per-
formed to assess the effect of antimicrobials on disease outcome.
Results. Among 3166 recruited participants (median age 10 months; interquartile range, 6.5–16.7 months), one-third (1096 
of 3166) had bloody diarrhea, and 25% (793 of 3166) were culture positive for Shigella, NTS, or Campylobacter. More than 85% of 
patients (2697 of 3166) were treated with antimicrobials; fluoroquinolones were the most commonly administered antimicrobials. 
AMR was highly prevalent among the isolated bacteria, including resistance against fluoroquinolones and third-generation cephalo-
sporins. Antimicrobial treatment and multidrug resistance status of the infecting pathogens were found to have no significant effect 
on outcome. Antimicrobial treatment was significantly associated with an increase in the duration of hospitalization with particular 
groups of diarrheal diseases.
Conclusions. In a setting with high antimicrobial usage and high AMR, our results imply a lack of clinical benefit for treating diar-
rhea with antimicrobials; adequately powered randomized controlled trials are required to assess the role of antimicrobials for diarrhea.
Keywords. nontyphoidal Salmonella; Campylobacter; Shigella; pediatric diarrhea; antimicrobial resistance; multidrug resistance; 
fluoroquinolones; disease outcome. 
Diarrhea remains the second most significant cause of morbidity 
and mortality in children aged <5 years worldwide [1]. In 2010, 
the global burden of diarrhea was estimated to be 1.73 billion 
episodes, of which 36 million were characterized as moderate or 
severe; 26% (9.3 million) of the severe episodes were estimated to 
arise in Southeast Asia [1]. Among the bacterial pathogens causing 
diarrhea in children Campylobacter spp., nontyphoidal Salmonella 
(NTS), Shigella spp., Escherichia coli, and Yersinia enterocolitica are 
the most commonly identified [2, 3]. Campylobacter, NTS, and 
Shigella are major contributors to the global morbidity of diarrhea 
and account for an estimated 7.5, 7.1, and 4.8 million disabili-
ty-adjusted life years, respectively; the majority of these occur in 
low- to middle-income countries (LMICs) [4].
The prevalence of all-cause diarrhea in children aged <5 years 
in Vietnam is estimated to be 7%–11% (Multiple Indicator Cluster 
Survey in 2000, 2006, and 2011 [5]) and accounts for as much as 
12% of all-cause deaths in this age group [6]. A large burden of 
diarrheal disease, combined with the lack of financial and diag-
nostic resources in Vietnam, means that the causative agents of 
most diarrheal episodes are never determined. As a consequence, 
antimicrobials are empirically administered to children with 
diarrhea based solely on clinical presentation. A previous study 
found that antimicrobials were prescribed in 38% of acute watery 
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diarrhea episodes in Vietnamese children found to be associated 
with a viral pathogen and in 60% of cases with unknown etiology 
[7]. The excessive use of antimicrobials in animals and humans 
in Southeast Asia has led to the current antimicrobial resistance 
(AMR) crisis in the region, with increasing resistance against 
many first-line antimicrobials, including fluoroquinolones and 
third-generation cephalosporins, in many gram-negative patho-
gens across the region [8]. Therefore, a better understanding of 
the bacterial agents of diarrhea, their corresponding AMR pro-
file, the impact of antimicrobial treatment on clinical outcome, 
and the effects of empirical antimicrobials is required.
Little has been reported regarding the disease burden and clin-
ical management of hospitalized pediatric diarrheal diseases in 
Vietnam. Although NTS, Campylobacter, and Shigella have been 
identified as major bacterial causes of diarrhea in Vietnamese 
children [7, 9–11], the epidemiology, AMR profiles, treatment, 
and the associated outcome of these bacteria in pediatric diar-
rhea have not been not well described. The Vietnamese health-
care system currently follows the World Health Organization 
(WHO) guidelines for treatment of pediatric diarrhea. These 
guidelines recommend the use of low-osmolarity oral rehydra-
tion solution, zinc, and ciprofloxacin or 1 of the 3 alternatives 
(pivmecillinam, azithromycin, or ceftriaxone) for all patients 
with bloody diarrhea, irrespective of age [12, 13]. However, as 
the prevalence of AMR in enteric pathogens increases across 
the region, it is uncertain how existing guidelines correspond 
to circulating AMR profiles, antimicrobial treatment practices, 
and patient outcomes in children hospitalized with diarrhea. 
Therefore, we conducted a prospective multicenter cross- 
sectional study in Ho Chi Minh City to improve the under-
standing of bacteria-associated diarrhea in Vietnamese children 
and to assess the duration of hospital stay in diarrheal patients 
infected with bacterial pathogens and receiving antimicrobials.
MATERIALS AND METHODS
Ethics
Ethical approval for this study was provided by the ethics com-
mittees of all 3 participating local hospitals and the University 
of Oxford Tropical Research Ethics Committee (OxTREC No. 
1045-13). Written consent from parents or legal guardians of all 
participants was obtained before enrollment.
Study Design and Enrollment
This study was a prospective, observational, multicenter cross-
sectional study to evaluate the etiology, epidemiology, and out-
comes in children (aged <16  years) hospitalized for diarrhea. 
Study participants were recruited from 3 tertiary hospitals 
(Children’s Hospital 1, Children’s Hospital 2, and the Hospital 
for Tropical Diseases) in Ho Chi Minh City, Vietnam, from May 
2014 to April 2016.
Children hospitalized with diarrhea, defined as ≥3 passages of 
loose stools within 24 hours [12] with ≥1 loose stool containing 
blood and/or mucus, were recruited into the study. Based on 
characteristics of the diarrheal stools and the duration of illness, 
participants were classified into 3 groups: acute nonbloody diar-
rhea (diarrhea with mucus, <14  days), acute bloody diarrhea 
(diarrhea with blood, <14  days), and persistent diarrhea (diar-
rhea with mucus and/or blood, ≥14 days). Children were not eli-
gible if they had suspected or confirmed intussusception at the 
time of enrollment. After enrollment, a short questionnaire was 
completed, and a fecal sample was collected and processed within 
24 hours. All enrolled patients were provided with the routine 
standard-of-care practices at each hospital. Treatment and proxy 
outcomes, including patient recovery status at 3 days after enroll-
ment and duration of hospitalization, were recorded by clinical 
staff at study sites. Patient status was recorded as “recovered” if 
the patient had <3 passages of loose stools in the past 24 hours 
or “improved” if the patient had fewer episodes of diarrhea and/
or less mucus and/or blood compared with status at enrollment.
Microbiological Methods
Fecal specimens were inoculated onto MacConkey agar (MC agar; 
Oxoid) and xylose-lysine-deoxycholate agar (Oxoid) and into 
selenite broth (Oxoid) and incubated at 37°C for 18–24 hours. 
Salmonella and Shigella were detected based on their character-
istic appearance on xylose-lysine-deoxycholate and MC agar and 
confirmed using matrix-assisted laser desorption/ionization time-
of-flight mass spectrometry (Bruker) and API20E (bioMerieux), 
following the manufacturer’s guidelines. Campylobacter was iden-
tified using Campylobacter selective agar (Oxoid) under microaer-
ophilic conditions, followed by Gram staining and microscopy.
Antimicrobial susceptibility testing was performed using 
the Kirby-Bauer disc diffusion method on Mueller-Hinton agar 
(Oxoid) for Salmonella and Shigella, and on blood agar contain-
ing 5% sheep blood for Campylobacter and interpreted using 
Clinical and Laboratory Standards Institute guidelines [14] 
(Supplementary Table S1). Multidrug resistance (MDR) was 
defined as nonsusceptibility to ≥1 agent in ≥3 antimicrobial cate-
gories listed in Supplementary Table S1. Microbiology results were 
reported to the collaborating hospitals within 3 days of sampling.
Statistical Analysis
Data were analyzed using Stata (version 11; StataCorp) and R 
(versions 3.2.2; R Foundation for Statistical Computing) soft-
ware. Figures were constructed with R software, using the 
ggplot2 [15] and prodlim packages. Descriptive comparisons 
between groups were conducted using nonparametric tests, 
including the Fisher exact test for categorical variables and the 
Mann-Whitney U test for continuous data. Statistical compar-
isons between >2 groups were conducted using the χ2 test and 
the Kruskal-Wallis test for categorical and continuous variables, 
respectively. Kaplan-Meier curves for length of hospital stay were 
compared between groups, using log-rank tests. The growth sta-
tus of participating patients was assessed using the WHO global 
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database on growth and nutrition [16], the Institute for Clinical 
Systems Improvement’s guidelines on preventing and managing 
obesity in children and adolescents [17], and the macro package 
for Stata software (version 11) developed by WHO.
An accelerated failure time (AFT) regression model (incorpo-
rating all study patients hospitalized for ≥1 day) was constructed 
in 3 steps. First, the best AFT distribution fit was identified for 
the dependent variable, that is, length of hospital stay. Second, 11 
demographic variables (eg, sex and age), clinical symptoms of dis-
ease severity, treatment types, and MDR were tested by means of 
univariate analysis, using a log-normal distribution. The 11 vari-
ables were chosen because of their potential to affect duration of 
hospital stay. Third, a multivariate log-normal model was con-
structed using a stepwise backward elimination method, where 
variables were removed based on the likelihood ratio test (P < .05).
RESULTS
General Characteristics of Patients Hospitalized With Diarrhea
Between May 2014 and April 2016, a total of 3166 hospitalized 
children meeting the study criteria were recruited at the 3 study 
hospitals. The majority of patients were male (1945 of 3166; 
61.4%), with ages ranging from 1 month to 15 years (median 
age, 10  months; interquartile range [IQR], 6.5–16.7  months). 
Patients were hospitalized for a median of 5 days (IQR, 3–7 days) 
with 88.7% (2808 of 3166) of patients showing improvement or 
resolving symptoms within 3 days of enrollment.
Patients were segregated into 3 diarrheal types: acute non-
bloody (1775 of 3166; 56.1%), acute bloody (1096 of 3166; 
34.6%), or persistent (295 of 3166; 9.3%) (Table 1). Owing to 
the clinical complexity of persistent diarrhea, statistical com-
parisons were conducted between the 2 acute diarrhea groups 
only. Patients with nonbloody diarrhea were more likely to 
experience vomiting than those with bloody diarrhea (66.8% 
vs 38.7%; P  =  .001) and dehydration (15.0% vs 2.6%, respec-
tively; P = .001). A significantly greater proportion of patients 
with bloody diarrhea experienced abdominal pain (26.4% vs 
19.3% of those with nonbloody diarrhea; P  =  .001). Systemic 
C-reactive protein (CRP) concentrations were significantly 
higher in patients with bloody than in those with nonbloody 
diarrhea (21.0 [IQR, 6.7–40.2] vs 7.0 [4.0–24.0] mg/L; P < .001).
We cultured the 3 key bacterial diarrheal pathogens in 
Vietnam (ie, NTS, Campylobacter, and Shigella), isolating 816 
pathogens from 804 patients (11 coinfections) and stratified 
clinical manifestations and treatment data by these organisms. 
At least 1 of these bacteria was isolated from the fecal specimens 
of 44.3% with bloody diarrhea (485 of 1096) and 17.9% (318 of 
1775)  with nonbloody diarrhea (P  <  .001) (Table  1). Overall, 
NTS was the most frequently isolated of the 3 bacterial path-
ogens from the diarrheal children, accounting for 15.1% (478 
of 3166) of all diarrheal cases, followed by Campylobacter and 
Shigella. Shigella infections were more common in older chil-
dren (median age, 3 years) and were associated with more severe 
symptoms. However, children with Shigella infections recovered 
more rapidly than those infected with NTS or Campylobacter 
(Supplementary Table S2).
Antimicrobial Usage for Treatment of Hospitalized Diarrheal Diseases
We also recorded the treatment regimens of the enrolled patients, 
which included oral rehydration solution, intravenous rehy-
dration, zinc, probiotics, and antimicrobials. More than 90% of 
patients were administered oral rehydration solution, and >80% 
were given zinc supplementation. The use of antimicrobials 
within this population was high, with 85.2% of patients (2697 of 
3166) receiving empirical antimicrobial treatment after admission 
to the hospital and before a bacterial culture result was obtained. 
Fluoroquinolones were the most commonly used class of antimi-
crobials (1799 of 2697; 66.7%). Differences in standard-of-care 
treatment were observed between patients with bloody versus 
nonbloody diarrhea (Table  1); antimicrobials were more regu-
larly administered to patients with bloody diarrhea than to those 
with nonbloody diarrhea (P < .001). Antimicrobials, specifically 
fluoroquinolones, were commonly (>70%) prescribed before an 
etiological diagnosis in those eventually found to be infected with 
Campylobacter, Salmonella, or Shigella (Supplementary Table S2).
Antimicrobial Susceptibility
Campylobacter, Salmonella, and Shigella isolates displayed 
a high prevalence of nonsusceptibility against many of the 
screened antimicrobials (Figure 1). Notably, a high proportion 
of Campylobacter, NTS, and Shigella exhibited nonsusceptibility 
against ciprofloxacin: 94.2% (242 of 257), 58.4% (279 of 478), 
and 70.4% (57 of 81), respectively. In addition, 56.8% of Shigella 
(46 of 81) and 13.8% of NTS (66 of 478) isolated were nonsus-
ceptible to the third-generation cephalosporins, ceftriaxone 
and ceftazidime. A smaller fraction of the Campylobacter, NTS, 
and Shigella isolates also exhibited resistance against azithromy-
cin: 9.7% (25 of 257), 17.4% (83 of 478), and 22.2% (18 of 81), 
respectively. The majority of the organisms (65.4%; 531 of 816 
isolates) were categorized as MDR. The prevalence of MDR was 
highest within the Campylobacter isolates (218 of 257; 84.8%), 
with 3 isolates also exhibiting nonsusceptibly to imipenem. 
The MDR prevalence in NTS and Shigella was 53.9% (258 of 
478) and 67.9% (55 of 81), respectively (Figure 1).
Diarrheal Disease Outcome
We assessed the effect of antimicrobial treatment on 2 proxy 
disease outcome measures, clinical outcome (ie, improved/
recovered) at 3 days after enrollment and the duration of hospi-
tal stay. More than 80% of patients showed improvement or had 
recovered at 3 days after enrollment, regardless of antimicrobial 
treatment (Supplementary Figure S1). However, those given 
an antimicrobial, specifically a fluoroquinolone, had a longer 
hospital stay than those not receiving an antimicrobial (P < .001 
and P =  .01, respectively) (Figure 2). Notably, the duration of 
hospital stay did not differ significantly between those receiving 
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and those not receiving an antimicrobial among patients with 
bloody diarrhea (Figure 2C). However, antimicrobial treatment 
in those with nonbloody diarrhea was significantly associated 
with a longer hospital stay (median [IQR] hospital stay for 
antimicrobial vs no antimicrobial use, 5 [3–7] vs 4 [3–5] days; 
P  <  .001; (Figure  2C). Similarly, antimicrobial treatment in 
patients with low CRP levels (≤5 mg/L) was significantly asso-
ciated with an increased hospital stay, compared with patients 
with high CRP levels (>5 mg/L) (P < .001; Figure 2D).
We then stratified all patients by antimicrobial treatment, 
and within those treated with antimicrobials we compared 
disease outcome (ie, duration of hospitalization) between 
those infected with MDR or non-MDR organisms and 
between those infected with fluoroquinolone-susceptible or 
nonsusceptible organisms. In patients empirically treated 
with any antimicrobial or a fluoroquinolone, >90% (526 of 
564)  and 70% (361 of 515)  were infected with an MDR or 
a fluoroquinolone nonsusceptible organism, respectively. 
However, regardless of the MDR status and fluoroquinolone 
nonsusceptibility of the infecting organisms, no differences in 
the duration of hospitalization were observed among patients 
treated with antimicrobials (Figure  3). Comparable findings 
were observed for recovery status at 3 days after enrollment 
(Supplementary Figure S1).
Table 1. Demographic and Clinical Manifestations of Pediatric Patients Admitted With Diarrhea in Ho Chi Minh Citya
Characteristics
Patients, No. (%)
P Valuec
Nonbloody Diarrhea 
(n = 1775)b
Bloody Diarrhea  
(n = 1096)
Persistent Diarrhea 
(n = 295)
Sociodemographic
 Male sex 1135 (63.9) 633 (57.8) 177 (60.0) .001
 Age, median [IQR], mo 11.5 [7.6–18.5] 9.0 [5.9–15.5] 5.5 [4.0–8.2] <.001
Growthd
 Obese or overweight 184 (11.0) 83 (8.3) 24 (8.7) .02
 Wasted or severely wasted 176 (10.5) 107 (10.6) 25 (9.1) .69
Clinical symptoms
 Episodes per day, median [IQR], No. 7 [5–10] 7 [5–10] 7 [5–10] …
 Moderate or severe dehydratione 267 (15.0) 28 (2.6) 9 (3.1) .001
 Abdominal pain 343 (19.3) 289 (26.4) 50 (17.0) .001
 Fever (≥37.5°C) at enrollment 1137 (64.1) 615 (56.1) 83 (28.2) .001
 Vomiting 1185 (66.8) 424 (38.7) 101 (34.4) .001
Hematology
 Neutrophil count, median [IQR], 103/μL 4.4 [2.6–7.0] 4.1 [2.4–6.7] 2.5 [1.6–3.9] .01
 CRP, median [IQR], mg/L 7.0 [4.0–24.0] 21.0 [6.7–40.2] 5.0 [3.3–7.0] <.001
Stool culture positive .7
 Campylobacter 100 (5.6) 155 (14.1) 2 (0.7) <.001
 Salmonella 179 (10.1) 289 (26.4) 10 (3.4) <.001
 Shigella 39 (2.2) 41 (3.7) 1 (0.3) .02
Treatment
 Low-osmolarity oral rehydration solution 1740 (98.0) 956 (87.2) 260 (88.1) .8
 Intravenous rehydration 278 (15.7) 48 (4.4) 15 (5.1) .001
 Antimicrobials 1392 (78.4) 1079 (98.4) 226 (76.6) .001
 Fluoroquinolonesf 739 (53.1) 920 (85.3) 140 (61.9) .001
 Zinc 1586 (89.4) 962 (87.8) 276 (93.6) .20
 Probiotics 1395 (78.6) 627 (57.2) 200 (67.8) .001
Outcome
 Hospital stay, median [IQR], d 5 [3–6] 4 [3–6] 9 [4–10] .003
 Improved or recovered after 3 dg 1624 (91.5) 961 (87.7) 223 (75.6) .008
Abbreviations: CRP, C-reactive protein; IQR, interquartile range.
aData represent No. (%) unless otherwise specified.
bAll children with nonbloody diarrhea had mucus in stools.
cP values represent comparisons between nonbloody and bloody diarrhea using Fisher exact test for categorical data or Mann-Whitney U test for continuous data.
dObese: weight for length z score >3 standard deviations [SDs] in children aged <24 months; body mass index (BMI) for age z score >3 SDs in children aged ≥24 months. Overweight: weight 
for length z score >2 SDs in children aged <24 months; BMI for age z score >2 SDs in children aged ≥24 months. Wasted: weight for length z score ≤2 SDs in children aged <24 months; 
BMI for age z score ≤2 SDs in children aged ≥24 months. Severely wasted: weight for length z score ≤3 SDs in children aged <24 months; BMI for age z score ≤3 SDs in children aged 
≥24 months [18].
eDehydration classified as described by Basaleem and Amin [19].
fPercentage of those receiving antimicrobials. Fluoroquinolones included ciprofloxacin and norfloxacin.
gCondition was described as “recovered” if patient had <3 passages of loose stool in the past 24 hours or “improved” if patient had fewer episodes of diarrhea and less mucus and/or blood 
than at enrollment.
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An AFT multiple regression model was considered to be an 
appropriate method for describing how each of the adjusted 
variables multiplicatively alters the duration of hospitalization. 
Therefore, an AFT was constructed to investigate the effect of 
antimicrobials on the duration of hospital stay, adjusting for age, 
disease severity, and other prescribed treatments. After adjust-
ment for age, diarrhea presentation, and dehydration, antimicro-
bials were associated with a significant increase in the duration 
of hospital stay of diarrheal patients by a time ratio of 1.32 [1.24–
1.41]. Finally, infection with an MDR organism was found to not 
significantly prolong hospitalization (P = .55; Table 2).
DISCUSSION
Moderate-to-severe diarrhea has a significant healthcare burden 
in Vietnamese children [20]. Although previous observational 
studies of diarrhea in Vietnam have described some of the 
epidemiological features, the bacterial causes, and their asso-
ciated AMR profiles, these studies have focused chiefly on 
children with acute watery diarrhea [7]. Little is known about 
the epidemiology and clinical management of bloody and/or 
mucoid diarrhea in Vietnam. Therefore, we aimed to address 
this paucity of data by enrolling >3000 of children hospital-
ized with diarrheal. This large sample size not only enabled the 
isolation of >800 enteric pathogens, but it also provided data 
regarding antimicrobial usage in medical practice and outcome. 
Furthermore, this study investigated the clinical role of AMR in 
a relevant population empirically prescribed antimicrobials at 
presentation to the hospital.
AMR in pathogenic bacteria, including those associated 
with diarrhea, is a global public health problem [21, 22]. Data 
Figure 1. The antimicrobial resistance profiles for isolated Campylobacter spp. (A), nontyphoidal Salmonella spp. (B), and Shigella spp. (C), showing antimicrobial sus-
ceptibility and multidrug resistance (MDR), defined as nonsusceptibility to ≥1 agent in ≥3 antimicrobial categories). Bar graphs shows proportion of organisms exhibiting 
nonsusceptibility (dark gray) to nalidixic acid (NAL), ciprofloxacin (CIP), ceftriaxone (CRO), ceftazidime (CAZ), amoxicillin-clavulanic acid (AMC), ampicillin (AMP), trimethop-
rim-sulfamethoxazole (SXT), azithromycin (AZM), chloramphenicol (CHL), amikacin (AMK), gentamicin (GEN), erythromycin (ERY), clindamycin (CLI), and IPM ( ).
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from Vietnam highlight the increasing trend in diarrheagenic 
bacteria of AMR to the current first-line antimicrobials, such 
as fluoroquinolones and third-generation cephalosporins. 
Moreover, despite recent increases in fluoroquinolone resist-
ance in Asia and beyond, current guidelines still endorse the 
use of this class of antimicrobials to treat bloody diarrhea 
[23–25]. Many of the organisms isolated during this investiga-
tion were also nonsusceptible to other (nonfluoroquinolone) 
antimicrobials, including some “last resort” choices, such as 
imipenem. 
In comparison to estimates from other industrializing coun-
tries, we observed a similar or elevated prevalence of NTS 
exhibiting nonsusceptibility to third-generation cephalospor-
ins and increased nonsusceptibility to both ciprofloxacin and 
azithromycin [26, 27]. An extraordinarily high prevalence 
(~90%) of fluoroquinolone-resistant Campylobacter has been 
recently observed in other industrializing countries [28, 29]. 
The situation in Vietnam seems to be exacerbated by the 
nonsusceptibility of Campylobacter isolates to macrolides. 
The Shigella isolated here also had a high MDR rate; emerg-
ing MDR Shigella isolates with resistance to fluoroquinolones 
and extended-spectrum cephalosporins are now commonly 
reported across Asia [10, 30, 31].
The treatment of diarrhea with antimicrobials is a com-
plex issue. Apart from the limited capability of most LMICs 
to confirm etiological agents associated with disease and the 
current complication of increasing AMR, there are conflicting 
data regarding the clinical efficacy of antimicrobials in reduc-
ing symptoms [33]. In line with WHO recommendations, we 
observed that >85% of patients hospitalized with diarrhea con-
taining mucus and/or blood were prescribed an antimicrobial, 
most commonly fluoroquinolones (ciprofloxacin/norfloxacin). 
Our current analysis found that antimicrobial use during hospi-
talized diarrhea did not add benefit to supportive therapy only 
(ie, rehydration and zinc supplementation). 
The recovery of patients regardless of antimicrobial treatment 
or AMR status when treated with a first-line antimicrobial for 
bloody diarrhea treatment (eg, ciprofloxacin) may be explained 
by either the differing in vivo effects of antimicrobials or the 
self-limiting nature of the infections. In addition, in diarrhea 
with less pronounced inflammation (indicated by the absence 
of blood and/or a low CRP level), the use of antimicrobials was 
associated with a prolonged hospital stay. These observations 
support previous findings in studies of NTS and Campylobacter, 
where antimicrobial treatment did not provide a clinical advan-
tage and sometimes even caused harm (compared with placebo) 
in decreasing the duration of symptoms [34, 35]. The routine 
antimicrobial treatment may also affect the transmission of 
diarrhea-causing bacteria by increasing fecal carriage and con-
sequently spreading AMR organisms [34].
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Figure 2. Effect of antimicrobial treatment on clinical outcome. A, B, Kaplan-Meier curves show days in the hospital for diarrheal children treated with antimicrobials (A) 
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The main limitation in the present study is that this investigation 
was observational, with patients receiving standard-of-care treat-
ment, which made it difficult to assess whether our observations 
were biased by more severe cases being prescribed antimicrobi-
als. Furthermore, the duration of hospital stay and recovery of 
patients at 3 days after enrollment were proxy measures of clinical 
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Figure 3. Effect of antimicrobial resistance on clinical outcome. A, B, Kaplan-Meier curves for length of hospital stay in diarrheal children treated with either antimicrobials 
or fluoroquinolones (FLQs) and stratified by multidrug resistance (MDR) (A) or FLQs resistance (B) profile of the isolated bacteria. C, D, Effect of MDR (C) and FLQ resistance 
(D) on the length of hospital stay in diarrheal children infected with Campylobacter, nontyphoidal Salmonella, and Shigella, while being treated with antimicrobials or FLQs, 
respectively. Statistical comparisons for categorical variables were conducted using the Kruskal-Wallis test. Log-rank tests were used to compare Kaplan-Meier curves for 
length of hospital stay between groups.
Table 2. Univariate and Multivariate Analysis of Diarrheal Symptoms and Treatment on Diarrheal Disease Outcome (Length of Hospital Stay) Using an 
Accelerated Failure Time (Log-Normal) Model
Variable
Univariate Model Final Multivariate Modela
β Value TR (95% CI)b P Value β Value TR (95% CI)b P Value
Age group
 0–6 mo 1 1 … 1 1 …
 7–12 mo −.075 0.93 (.88–.98) .01 −.106 0.90 (.85–.95) <.001
 13–60 mo −.188 0.83 (.78–.88) <.001 −.231 0.79 (.75–.84) <.001
 >60 mo −.381 0.68 (.59–.79) <.001 −.445 0.64 (.56–.74) <.001
Sex
 Female 1 1 … 1 1 …
 Male .017 1.02 (.97–1.07) .44 … … …
Diarrhea type
 Nonbloody 1 1 … 1 1 …
 Bloody −.059 0.94 (.90–.98) .01 −.122 0.89 (.84–.93) <.001
Fever −.047 0.95 (.88–1.03) .26 … … …
Dehydration .193 1.21 (1.13–1.31) <.001 .179 1.20 (1.11–1.29) <.001
Abdominal pain −.049 0.95 (.90–1.01) .10 … … …
Probiotic treatment .067 1.07 (1.02–1.12) .005 … … …
Zinc treatment .043 1.04 (.97–1.12) .23 … … …
Rehydration .081 1.08 (.99–1.18) .07 … … …
Antimicrobial use .229 1.26 (1.18–1.34) <.001 .279 1.32 (1.24–1.41) <.001
MDR −.027 0.97 (.89–1.06) .55 … … …
Abbreviations: CI, confidence interval; MDR, multidrug resistance; TR, time ratio.
aAdjusted β and TR values from the multivariable log-normal analysis.
bTRs >1 indicate an extended hospital stay; TRs <1, a decreased stay.
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outcome, and we cannot discount that some children may have 
been discharged before the cessation of symptoms.
In conclusion, bacteria associated with pediatric diarrhea in 
southern Vietnam displayed an extensive AMR profile, thereby 
emphasizing the significance of etiological diagnosis of diarrhea 
in LMICs. Our key finding was that antimicrobial treatment was 
not associated with a reduction in diarrheal symptoms and even 
prolonged hospital stay in some groups. Therefore, we urge that 
adequately powered randomized controlled trials be conducted 
to better assess the potential benefits of antimicrobial therapy 
for treatment of diarrhea. These data will become essential for 
controlling antimicrobial usage during the present AMR crisis.
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